Skip to content

US · HURA · BIOTECHNOLOGY

TuHURA Biosciences, Inc. (HURA) intrinsic value and stock valuation

$1.25as of 2026-11-21 · Mkt cap 133.1M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TuHURA Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values HURA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HURA’s statements →

TuHURA Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tampa, FL 33612 tuhurabio.com

How the business is doing

Fiscal 2010–2025, USD

Revenue
$0.00
20102025
Net income
-$-30.06M
20102025
Free cash flow
-$-27.71M
20152025
Total equity
$20.9M+140.5% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2010–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-31.8M-$-17.65M-$-8.45M-$-14.8M-$-22.68M
Net income-$-30.06M-$-21.68M-$-8.32M-$-14.65M-$-22.66M
EPSd-$-627.16K-$-1.16M-$-11.09M-$-293M-$-755.33M
Operating cash flow-$-27.63M-$-14.73M-$-11.95M-$-7.51M-$-6.56M
Capital expenditure-$-80K-$-60K-$-80K-$-230K-$0.00
Free cash flow-$-27.71M-$-14.79M-$-12.03M-$-7.54M-$-6.57M
Total assets$27.4M$20M$4.36M$15.2M$6.4M
Total debt$700K$200K$2.34M$140K$640K
Net debt-$-2.92M-$-12.45M-$-1.32M-$-14.11M-$-4.9M
Total equity$20.9M$14.6M-$-1.56M$12.3M-$-750K
Cash and short-term investments$3.62M$12.7M$3.67M$14.3M$5.55M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$60K$60K$60K
Gross profit$0.00$0.00-$-60K-$-60K-$-60K
Research and development expenses$20.5M$13.3M$2.66M$9.31M$15.2M
Selling, general and administrative expenses$7.58M$3.87M$5.73M$5.42M$7.45M
Other expenses$3.68M$440K$0.00$0.00$0.00
Operating expenses$31.8M$17.7M$8.4M$14.7M$22.6M
Cost and expenses$31.8M$17.7M$8.45M$14.8M$22.7M
Interest income$140K$360K$90K$60K$0.00
Interest expense$630K$4.14M$20K$0.00$630K
Depreciation and amortization$70K$120K$60K$60K$60K
Ebitda-$-29.36M-$-17.43M-$-8.27M-$-14.59M-$-21.97M
Operating income-$-31.8M-$-17.65M-$-8.45M-$-14.8M-$-22.68M
Total other income/expenses, net$1.74M-$-4.03M$130K$150K$20K
Income before tax-$-30.06M-$-21.68M-$-8.32M-$-14.65M-$-22.66M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-30.06M-$-21.68M-$-8.32M-$-14.65M-$-22.66M
Weighted average shares outstanding$47.9M$18.7M$750K$50K$30K
Weighted average diluted shares outstanding$47.9M$18.7M$750K$50K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$3.62M$12.7M$3.67M$14.3M$5.55M
Net receivables$0.00$220K$330K$100K$0.00
Inventory$0.00$210K$0.00$0.00$0.00
Total current assets$4.62M$19.6M$4.16M$14.7M$5.68M
Property, plant and equipment, net$690K$320K$200K$420K$620K
Goodwill and intangible assets$10.7M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$22.7M$360K$200K$450K$720K
Total assets$27.4M$20M$4.36M$15.2M$6.4M
Accounts payable$3.77M$3.15M$1.87M$1.92M$410K
Short-term debt$400K$160K$20K$120K$640K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.92M$5.33M$3.6M$2.87M$7.15M
Long-term debt$300K$40K$2.32M$20K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$500K$40K$2.32M$20K$0.00
Capital lease obligations$200K$200K$20K$140K$0.00
Total liabilities$6.42M$5.37M$5.92M$2.89M$7.15M
Common stock$60K$40K$10K$0.00$0.00
Retained earnings-$-141.18M-$-111.12M-$-88.47M-$-59.16M-$-49.48M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$20.9M$14.6M-$-1.56M$12.3M-$-750K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$700K$200K$2.34M$140K$640K
Net debt-$-2.92M-$-12.45M-$-1.32M-$-14.11M-$-4.9M
Cash flow statement
20252024202320222021
Net income-$-30.05M-$-21.68M-$-29.32M-$-9.37M-$-7.02M
Depreciation and amortization$70K$120K$180K$370K$380K
Stock-based compensation$6.42M$1.96M$480K$220K$650K
Change in working capital-$-3.15M$3.29M$490K$1.56M-$-60K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-27.63M-$-14.73M-$-7.18M-$-7.51M-$-6.56M
Investments in property, plant and equipment-$-80K-$-60K-$-80K-$-40K-$0.00
Acquisitions, net-$-1.26M-$-5.99M-$-1.22M$0.00$0.00
Net cash used for investing activities-$-1.34M-$-6.05M-$-1.3M-$-40K-$0.00
Common stock issued$21.9M$5M$10.6M$1.9M$5.6M
Common stock repurchased$0.00$0.00-$-20K$0.00$0.00
Dividends paid-$-10K$0.00-$-10K-$-10K-$-10K
Net cash used for financing activities$19.9M$29.8M$2.66M$16.3M$7.04M
Net change in cash-$-9.04M$8.99M-$-10.59M$8.71M$480K
Cash at end of period$3.62M$12.7M$3.67M$14.3M$5.55M
Operating cash flow-$-27.63M-$-14.73M-$-11.95M-$-7.51M-$-6.56M
Capital expenditure-$-80K-$-60K-$-80K-$-230K-$0.00
Free cash flow-$-27.71M-$-14.79M-$-12.03M-$-7.54M-$-6.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TuHURA Biosciences, Inc.

        TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

        CEO
        James A. Bianco
        Employees
        22
        Beta
        -0.01

        Explore

        Frequently asked questions

        What is the intrinsic value of TuHURA Biosciences, Inc. (HURA)?

        InvestorsCraft does not currently publish an intrinsic value for HURA. How the IC value is calculated.

        Is HURA undervalued?

        InvestorsCraft does not publish an undervaluation signal for HURA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.